USPTO serial 79258264
HUB
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 12, 2020
- Examiner
- MOLINOFF, JEFFREY S.
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with HUB?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,446*
Plus Government fees of $1,700
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
NL
Stichting Hubrecht Organoid Technology
NL
Other trademarks owned by Stichting Hubrecht Organoid Technology
NL
Stichting Hubrecht Organoid Technology
NL
Other trademarks owned by Stichting Hubrecht Organoid Technology
DE
Stichting Hubrecht Organoid Technology
NL
Other trademarks owned by Stichting Hubrecht Organoid Technology
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
William C. Wright
William C. Wright Epstein Drangel LLP60 E 42nd Street, Suite 1250New York, NY 10165United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Cells, stem cells, epithelial cells, all for scientific research purposes; organoids, namely, self-organized three-dimensional tissue cultures derived from stem cells and cell cultures, for scientific and research use; cell culture reagents for scientific and research use; cell culture media for scientific and research use; diagnostic preparations and reagents for use in science; chemicals used in science and industry; assays and assay reagents for scientific purposes; cell culture media for scientific research purposes | ACTIVE | — |
| 005 | Cells for medical and veterinary diagnostic and therapeutic purposes, namely for diagnosis and treatment of diseases or disorders of epithelial tissue in the sensory, reproductive, urinary, digestive, circulatory, endocrine, nervous, lymphatic, integumentary, or respiratory systems; cells for medical and veterinary diagnostic and therapeutic purposes, namely for diagnosis and treatment of diseases of epithelial tissue in the liver, pancreas, intestine, stomach, prostate, lung, breast, kidney, ovarian, uterus, fallopian tube, sweat gland, hair follicle, skin, oesophagus, thyroid, nose, throat, sinus, trachea, oral cavity, salivary gland, larynx or pharynx; stem cells for medical and veterinary diagnostic and therapeutic purposes, namely for diagnosis and treatment of diseases or disorders of epithelial tissue in the sensory, reproductive, urinary, digestive, circulatory, endocrine, nervous, lymphatic, integumentary, or respiratory systems; stem cells for medical and veterinary diagnostic and therapeutic purposes, namely for diagnosis and treatment of diseases of epithelial tissue in the liver, pancreas, intestine, stomach, prostate, lung, breast, kidney, ovarian, uterus, fallopian tube, sweat gland, hair follicle, skin, oesophagus, thyroid, nose, throat, sinus, trachea, oral cavity, salivary gland, larynx or pharynx; epithelial cells for medical and veterinary diagnostic and therapeutic purposes, namely for diagnosis and treatment of diseases or disorders of epithelial tissue in the sensory, reproductive, urinary, digestive, circulatory, endocrine, nervous, lymphatic, integumentary, or respiratory systems; epithelial cells for medical and veterinary diagnostic and therapeutic purposes, namely for diagnosis and treatment of diseases of epithelial tissue in the liver, pancreas, intestine, stomach, prostate, lung, breast, kidney, ovarian, uterus, fallopian tube, sweat gland, hair follicle, skin, oesophagus, thyroid, nose, throat, sinus, trachea, oral cavity, salivary gland, larynx or pharynx; organoids, namely, self-organized three-dimensional tissue cultures derived from stem cells and cell cultures for medical and veterinary diagnostic and therapeutic purposes namely for diagnosis and treatment of diseases or disorders of epithelial tissue in the sensory, reproductive, urinary, digestive, circulatory, endocrine, nervous, lymphatic, integumentary, or respiratory systems; organoids, namely, self-organized three-dimensional tissue cultures derived from stem cells and cell cultures for medical and veterinary diagnostic and therapeutic purposes namely for diagnosis and treatment of diseases of epithelial tissue in the liver, pancreas, intestine, stomach, prostate, lung, breast, kidney, ovarian, uterus, fallopian tube, sweat gland, hair follicle, skin, oesophagus, thyroid, nose, throat, sinus, trachea, oral cavity, salivary gland, larynx or pharynx; cell cultures for medical and veterinary diagnostic and therapeutic purposes, namely, cells grown in culture media for use in diagnosis and treatment of diseases or disorders of epithelial tissue in the sensory, reproductive, urinary, digestive, circulatory, endocrine, nervous, lymphatic, integumentary, or respiratory systems; cell cultures for medical and veterinary diagnostic and therapeutic purposes, namely, cells grown in culture media for use in diagnosis and treatment of diseases of epithelial tissue in the liver, pancreas, intestine, stomach, prostate, lung, breast, kidney, ovarian, uterus, fallopian tube, sweat gland, hair follicle, skin, oesophagus, thyroid, nose, throat, sinus, trachea, oral cavity, salivary gland, larynx or pharynx; diagnostic and analytical preparations for medical purposes; biological tissue cultures for medical and veterinary purposes; assays and assay preparations for medical and veterinary diagnostic testing of cells, cultures and organoids for therapeutic purposes; pharmaceutical and veterinary preparations for diagnosis and treatment of diseases or disorders of epithelial tissue in the sensory, reproductive, urinary, digestive, circulatory, endocrine, nervous, lymphatic, integumentary, or respiratory systems; pharmaceutical and veterinary preparations for diagnosis and treatment of diseases of epithelial tissue in the liver, pancreas, intestine, stomach, prostate, lung, breast, kidney, ovarian, uterus, fallopian tube, sweat gland, hair follicle, skin, oesophagus, thyroid, nose, throat, sinus, trachea, oral cavity, salivary gland, larynx or pharynx; cells, epithelial cells, organoids and cell cultures for personalised medicine, namely, for diagnosis and treatment of diseases or disorders of epithelial tissue in the sensory, reproductive, urinary, digestive, circulatory, endocrine, nervous, lymphatic, integumentary, or respiratory systems; cells, epithelial cells, organoids and cell cultures for personalised medicine, namely, for diagnosis and treatment of diseases of epithelial tissue in the liver, pancreas, intestine, stomach, prostate, lung, breast, kidney, ovarian, uterus, fallopian tube, sweat gland, hair follicle, skin, oesophagus, thyroid, nose, throat, sinus, trachea, oral cavity, salivary gland, larynx or pharynx | ACTIVE | — |
| 042 | Scientific research; genetic testing for scientific research purposes; medical and pharmacological research services; pharmaceutical drug and vaccine development services; development of pharmaceutical preparations and medicines; medical compound, drug and vaccine discovery, development services, and characterization and validation services in the nature of product quality and efficacy testing for medical compounds, drugs and vaccines; candidate drug and vaccine, drug and vaccine testing services, namely, testing of pharmaceuticals; companion diagnostics, namely, the scientific testing and evaluation of drugs and vaccines for individuals or groups of patients to determine the safety and effectiveness of the drug or vaccine for those patients; food safety testing services; testing of compounds and substances to determine toxicity to cells and organoids, namely, self-organized three-dimensional tissue cultures derived from stem cells and cell cultures; scientific research and diagnostic services in the field of personalized medicine | ACTIVE | — |
| 044 | Medical services and surgery; medical and surgical diagnostic services; medical services in the nature of cell transplantation services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by HUB Organoids B.V. IP
- Other trademarks owned by Stichting Hubrecht Organoid Technology
- Other trademarks owned by HUB Organoids IP B.V.
- Other trademarks owned by Stichting Hubrecht Organoid Technology
- Other trademarks owned by Merck KGaA
- Other trademarks owned by Stichting Hubrecht Organoid Technology
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named HUB
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 17, 2026 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Oct 28, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 28, 2025 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Oct 28, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 28, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 28, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 28, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| May 12, 2025 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| May 7, 2024 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Apr 5, 2024 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Oct 3, 2020 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Sep 15, 2020 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Sep 15, 2020 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Aug 12, 2020 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 12, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 25, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 25, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 22, 2020 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Feb 5, 2020 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 5, 2020 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Feb 5, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 22, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 22, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 22, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 22, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 22, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 21, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 17, 2020 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jan 14, 2020 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Jan 6, 2020 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Jan 1, 2020 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 1, 2020 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 1, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 19, 2019 | ALIE | ASSIGNED TO LIE | — |
| Dec 17, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 17, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 17, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 17, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 17, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 5, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 5, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 5, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 1, 2019 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 8, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 8, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 28, 2019 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jun 10, 2019 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jun 10, 2019 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 29, 2019 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 28, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 14, 2019 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 10, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| May 10, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 9, 2019 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |